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portive care were cost-drivers in total medical costs
during chemotherapy. In this study, we comprehensively
investigated medical costs from diagnosis through termi-
nal care in patients with advanced or recurrent gastric
cancer. METHODS: Patients with advanced or recurrent
gastric cancer who received the newly developed oral 
ﬂuoropyrimidine TS-1 or conventional intravenous
chemotherapy were identiﬁed on the basis of ordering
system data at Showa University Hospital from January
1998 through July 2001. The costs during diagnosis,
chemotherapy, and terminal care were evaluated accord-
ing to Japanese National Health Insurance fee schedule.
RESULTS: Costs were evaluated in 13 patients receiving
TS-1 and in 10 patients receiving conventional intra-
venous chemotherapy. Monthly costs during diagnosis,
chemotherapy, and terminal care in the TS-1 group were
597,057 +/- /105,148 (mean +/- SE) Yen, 327,640 
+/1 47,647 Yen, and 687,595 +/- /96,276 Yen. The 
corresponding costs for conventional intravenous
chemotherapy were 615,150 +/1/95,299 Yen, 852,874
+/-/ 62,412 Yen, and 619,721 +/-/ 86,745 Yen. Monthly
costs during chemotherapy were signiﬁcantly lower in 
the TS-1 group than in the conventional intravenous
chemotherapy group, whereas costs during diagnosis and
terminal care were similar in the groups. CONCLU-
SIONS: Medical costs from diagnosis through terminal
care are high in patients with advanced or recurrent
gastric cancer. The use of oral anticancer drugs such as
TS-1, which facilitates transition from inpatient to ambu-
latory treatment, reduces medical costs in patients with
gastric cancer.
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Data on head and neck cancer (HNSCC) is lacking, espe-
cially in France. OBJECTIVES: Estimate the costs of
inoperable HNSCC patients treated in the private sector
and their relationship with patient’s medical characteris-
tics. METHODS: We conducted a cohort study in one
centre to collect medical data from diagnosis until date
of last news or death. Reimbursements of medical fees
were obtained from the French Sickness Fund. For the
private sector, fee for service rules are applied; as a con-
sequence, all types of health care consumptions could be
identiﬁed. Consumptions were further linked to treatment
phases (initial treatment, follow-up, palliative care) and
medical events (chemotherapy, radiotherapy, relapse,
adverse event . . .). Logistic regression was carried out to
identify which of the medical characteristics (perfor-
mance, status, staging, age, localisation) were the main
cost drivers. Thirty patients were included and mean
duration of follow-up was 13.8 months. Mean total direct
costs was estimated at €20,752 per patient, with more
than one half for initial radio-chemotherapy (€11,399)
phase, around one quarter for follow-up (€4684) and the
same for palliative care (€4669). 14 patients died during
the study and only 9 received palliative care for an
average cost per treated patient of €15,563. RESULTS:
Type of care distribution varied according to treatment
phases with more hospitalisations and medical proce-
dures during initial treatment, more medication during
follow-up and more hospitalisation costs during pallia-
tive care. Costs of side effects were very high, particu-
larly those associated with mucositis that concerned all
patients with a mean cost of €4582 of which €1607 for
hospitalisation. CONCLUSIONS: Logistic regression
highlighted the importance of the nodal staging on the
mean total cost per patients and on the daily cost: €35
for AJCC stage III, €55 for stage IVa, €93 for stage IVb
patients.
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OBJECTIVES: The prognosis of non-small cell lung
cancer (NSCLC) patients is determined by mediastinal
lymph node involvement at the time of diagnosis. The
objective of this study was to investigate the cost conse-
quences of using endoscopic ultrasonography with ﬁne-
needle aspiration (EUS-FNA) instead of mediastinoscopy
(MS) or explorative thoracotomy (ET) in patients with
NSCLC and suspected mediastinal involvement on
positron emission tomography (PET). METHODS:
Potentially operable patients with NSCLC and positive
PET were eligible. If EUS-FNA was negative or inconclu-
sive, patients underwent MS. If MS was negative, ET was
performed. If EUS-FNA was positive for malignancy, no
ET was performed. The primary outcome was the reduc-
tion of invasive diagnostic procedures and as a result, the
reduction of direct medical costs, assessed from the hos-
pital viewpoint. The time horizon was the diagnostic tra-
jectory until discharge from the hospital. RESULTS:
Of 82 patients, 49 (60%) had positive EUS-FNA, and 
did not undergo invasive diagnostic procedures. In 33
patients (40%) EUS-FNA was either negative (6) or
inconclusive (27). Surgical staging by MS or ET was per-
formed in 26 of these 33 patients: 12 patients underwent
MS, nine patients had ET, and four patients both proce-
dures. The costs were $1590 for MS and $5822 for ET.
The costs for EUS-FNA were $591. Assuming that,
without EUS-FNA, all patients would undergo MS, and
15% would need additional ET to reach a diagnosis, the
differences in total costs were calculated at $55,000.
CONCLUSIONS: Introduction of EUS-FNA in the diag-
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nostic work-up of NSCLC patients’ leads to a reduction
of invasive procedures, resulting in cost savings of $669
per patient.
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OBJECTIVES: This study estimates the total health care
costs of ﬁve chemotherapeutic agents used to treat non-
small cell lung cancer (NSCLC) in Poland. This informa-
tion can be used to determine the most cost-efﬁcient
treatment option for health care providers in Poland.
METHODS: Two economic evaluations comparing 
gemcitabine/cisplatin (Gem/Cis) with four other novel
regimens were conducted using evidence from relevant
randomised controlled trials. The economic evaluation
based on the trial by Comella et al. (2000) compares
Gem/Cis with vinorelbine/cisplatin (Vin/Cis), while the
economic evaluation based on the trial by Schiller et al.
(2002) compares Gem/Cis with paclitaxel/cisplatin
(Pac/Cis), paclitaxel/carboplatin (Pac/Car), and doc-
etaxel/cisplatin (Doc/Cis). RESULTS: The economic eval-
uation based on the Comella et al. trial indicates that the
Gem/Cis combination is virtually cost neutral compared
to the Vin/Cis combination, costing an average of PLN
110 (€25) more per patient. The higher acquisition costs
of gemcitabine compared to vinorelbine were offset by
lower drug administration costs and lower rates of hos-
pitalisation for Gem/Cis patients. The economic evalua-
tion based on the Schiller et al. (2002) trial showed that
patients treated with Gem/Cis incurred higher total treat-
ment costs than those treated with Pac/Cis, by an average
of PLN 2880 (€652) per patient. However, patients
treated with Gem/Cis incurred signiﬁcantly lower total
treatment costs than those treated with Pac/Car and
Doc/Cis. The average cost savings associated with
Gem/Cis were PLN 1829 (€414) per patient and PLN
3921 (€888) per patient, respectively. CONCLUSIONS:
In Poland, Gem/Cis is the most advantageous treatment
alternative based on cost-minimisation for two out of 
the four comparators (Pac/Car and Doc/Cis). Using a
cost-effectiveness analysis, Gem/Cis is considered cost-
effective against the other two comparators (Vin/Cis 
and Pac/Cis). Overall, a claim for cost-effectiveness of
Gem/Cis regimens in the treatment of advanced NSCLC
is supported.
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OBJECTIVES: Complexed Prostate Speciﬁc Antigen
(cPSA) testing offers an improved speciﬁcity compared to
currently applied total PSA (tPSA) in the diagnosis of
prostate cancer in patients at risk. Our objective was to
assess the cost of cPSA if it would replace tPSA as ﬁrst
diagnostic test, based on medical management and cost
data for Belgium. Both tests have the same unit cost.
METHODS: A medical decision tree simulating a
patient’s ﬂow and applying a time horizon of one year
was developed in MS-Excel. Sensitivity and speciﬁcity
data were obtained from published directly comparative
clinical literature. An expert panel with 19 members (7
urologists and 12 general practioners) provided input
data regarding the further diagnostic work-up in case of
a positive PSA test and further therapeutical decisions and
medical resource use in relation to the diagnostic out-
comes (true and false positives and negatives). Costs of
medical resources were obtained from the public health
insurance perspective. RESULTS: When aiming for a
target sensitivity of 90%, a diagnosis starting with cPSA
costs €86.65 in total compared to €91.61 for tPSA. In a
second analysis, if published manufacturer cut-off values
were applied rather than a target sensitivity, total costs
were €75.50 and €91.60 respectively. The savings were
respectively €4.95 and €16.10 in favour of cPSA per
patient. For a yearly cohort of 500,000 men, savings up
to €8Mln could be realised. Sensitivity analyses on preva-
lence of prostate cancer and costs of diagnostic work-up
showed that the results were robust (savings range
€4.45–€5.46 in ﬁrst analysis and €13.3–€18.8 in second).
CONCLUSIONS: cPSA as standard screening test in
prostate cancer in patients at risk appears to have a strong
saving potential compared to the current use of tPSA.
Further research should focus on the psychological
impact of less false positive results.
CANCER—Quality of Life
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CHEMOTHERAPY TREATMENT REGIMENS
Viens P1, Namer M2, Selle F3
1Institut Paoli Calmettes, Marseille, France; 2Centre Antoine
Lacassagne, Nice, France; 3Hôpital Tenon, Paris, France
OBJECTIVE: To evaluate patient preference and Quality
of Life (QoL) with the administration of ﬁlgrastim versus
pegﬁlgrastim during myelosuppressive chemotherapy.
METHODS: Nine centres in France and 2 in Portugal
participated. The study was designed as an open-label,
cross-over trial with 76 cancer patients receiving 3 to 6
cycles of chemotherapy. Subjects were randomised on a 
1 :1 ratio to receive either multiple ﬁlgrastim injections
per cycle or pegﬁlgrastim as a single, ﬁxed-dose injection
once per cycle. In cycle 2, patients received the other study
medication. On day 1 of cycle 3, they were asked to com-
plete the Subject Preference Questionnaire to indicate
their preference for the remainder of the cycles. Data
